bluuebunny/crossref_metadata_2025_split huggingface dataset:
Long-term serial changes of cardiac sympathetic nerve dysfunction in acute decompensated heart failure patients with reduced, mid-range and preserved left ventricular ejection fraction
Authors: Seo M , Yamada T , Watanabe T , Morita T , Furukawa Y , Tamaki S , Kawasaki M , Kikuchi A , Kawai T , Fukunami M 
Published: November 2020

Abstract

Background
Cardiac sympathetic nerve dysfunction, which is assessed by I-123 metaiodobenzylguanidine (MIBG) imaging, is associated with the poor outcomes in patients with chronic heart failure (CHF). Serial evaluation of cardiac MIBG imaging was shown to be useful for predicting adverse outcome in CHF. However, there was no information available on long-term serial changes of cardiac sympathetic nerve dysfunction after discharge of acute decompensated heart failure (ADHF) hospitalization.

Purpose
We aimed to clarify the serial change of cardiac MIBG imaging parameter in long-term after discharge of heart failure hospitalization, especially relating to HFrEF (LVEF&lt;40%), HFmrEF (40%≤LVEF&lt;50%) and HFpEF (LVEF≥50%).

Methods
We studied 112 patients (HFrEF; n=44, HFmrEF; n=23 and HFpEF; n=45) who were admitted for ADHF, discharged with survival and without heart failure hospitalization during follow-up period. All patients underwent cardiac MIBG imaging at the timing of discharge, in 6–12 months and in 18–24 months after discharge. The cardiac MIBG heart to mediastinum ratio (H/M) was calculated on the early image and the delayed image (late H/M). The cardiac MIBG washout rate (WR) was calculated from the early and delayed planar images after taking radioactive decay of I-123 into consideration.

Results
In HFrEF patients, late H/M was significantly improved from discharge to 6–12 months data (1.60±0.24 vs 1.75±0.31, p&lt;0.0001). Late H/M of HFmrEF patients was also significantly improved from discharge to 18–24 months data (1.71±0.27 vs 1.84±0.29 p=0.043). On the other hand, late H/M of HFpEF patients was not significantly changed. As for WR, WR in HFrEF and HFmrEF patients was significantly improved from discharge to 18–24 months data, although WR of HFpEF was not significantly changed.

Conclusion
The improvement in cardiac sympathetic nerve dysfunction was observed in patients with HFrEF and HFmrEF, not in HFpEF, after the discharge of acute heart failure hospitalization.

Funding Acknowledgement
Type of funding source: None
The impact of stem cell therapy in chronic ischaemic heart disease and congestive heart failure: an updated cochrane systematic review and meta-analysis of randomised controlled trials
Authors: Weeraman D , Hadyanto S , Jones D , Mathur A 
Published: November 2020

Abstract

Introduction
Controversies in stem cell research (Anversa retractions) have led many to question the validity of clinical cell therapy research. There is however consistent data supporting the use of cell therapy for chronic IHD.

Purpose
To update the clinical evidence for the safety and efficacy of autologous adult bone marrow-derived stem/progenitor cells as a treatment for chronic IHD and CHF.

Methods
A full Cochrane review of relevant trials up to 21st November 2018 was performed. Randomised controlled trials comparing autologous adult stem/progenitor cells with no cells in participants with chronic IHD and CHF were deemed eligible. Trials that involved acute myocardial infarction were excluded.

Results
In total 41 randomised controlled trials and 2397 patients are included in the meta-analysis. This updated Cochrane review shows a statistically significant reduction in mortality (RR 0.51; 95% CI, 0.37 to 0.68; p≤0.00001) and MACE (RR 0.66; CI 0.55 to 0.80; p&lt;0.00001) seen with cell therapy. This is associated with a significant improvement in symptoms (exercise tolerance, NYHA, CCS) and ejection fraction.

Conclusions
Cell therapy may be effective for this patient group both for cardiovascular outcomes and symptom control. This conclusion therefore warrants further testing of cell therapy in prospective clinical trials assessing meaningful clinical endpoints.
Stem cell therapy and risk of all-cause

Funding Acknowledgement
Type of funding source: None
The developing mechanism of atherosclerotic lesion in coronary side branch on the ventricular free wall differs by the location of lesion
Authors: Yamanaka Y , Fujimori Y , Hashimoto S , Kurihara K , Wakabayashi T , Imai T , Baba T , Takeuchi W , Yokota D 
Published: November 2020

Abstract

Background
The effective treating method of coronary side branch lesions such as ostial stenosis or thin arteries has not been established. On the other hand, tortuous side branch rarely has stenotic lesions.

Purpose
We focused on coronary side branches on the ventricular free wall, and examined coronary risk factors and bending and stretching motion of branch which can contribute to the development of atherosclerotic lesion.

Methods
In elective and first-time coronary angiograms, we included side branches on the ventricular free wall (&gt;2mm in diameter) and excluded previously treated ones. Study A; we divided arteries into proximal, middle, and distal segment, and examined the presence of tortuosity and stenotic lesions exceeding 50% diameter stenosis (DS) for each segment. A score of 1 was assigned to tortuous segment, and 0 to non-tortuous one. Study B; we included stenotic lesion (&gt;50% DS) in side branch ostium and excluded those extended across main coronary arteries. Relation between lesions and patients' characteristics was examined.

Results
Study A; in 1,828 side branches from 472 patients, middle and distal segments had significantly higher tortuosity score than proximal (0.68, 0.78 vs. 0.34; p&lt;0.0001). On the contrary, proximal segments had more stenotic lesions except ostial stenosis (230 vs. 69, 5; p&lt;0.0001). Study B; in 1,740 side branches from 465 patients, 122 ostial stenotic lesions were found (7.0%). Multivariate logistic regression analysis revealed diabetes mellitus and age as independent contributors to development of ostial stenosis (Table).

Conclusions
Side branch stenosis developed less frequently in middle and distal segments, where stronger ventricular wall motion reinforces bending and stretching motion and tortuosity of arteries. This fact indicates that those characteristics may prevent developing atherosclerosis through increasing shear stress. On the other hand, diabetes mellitus strongly contributes to the development of ostial stenosis. Thus, the developing mechanism of atherosclerotic lesion in side branch on the ventricular free wall differs by the location of lesion.

Funding Acknowledgement
Type of funding source: None
Chemerin in coronary artery disease patients
Authors: Szpakowicz A , Kaminski K.A , Szpakowicz M , Lapinska M , Paniczko M , Lawicki S , Glazewska K , Raczkowski A , Kondraciuk M , Sawicka E , Kozuch M , Poludniewski M , Kowalska I 
Published: November 2020

Abstract

Background
Chemerin – a recently described hormone is secreted by adipose tissue. It exerts proinflammatory action, leads to insulin resistance, but also has potentially favorable effects: it increases eNOS activity and is pro-angiogenic. Increased serum concentrations of chemerin was observed in patients with coronary artery disease (CAD). The role of chemerin in pathogenesis of CAD is not well understood.

Purpose
The aim of this pilot study was to assess the role of chemerin in pathogenesis of atherosclerosis, its impact on condition of large arteries and prognosis in CAD.

Methods
We included in the study patients with stable CAD who underwent percutaneous coronary intervention (PCI) in the past. Chemerin levels were measured with ELISA method. All patients had routine blood tests and insulin levels measured. Patients without history of diabetes also had OGTT. Status of large arteries was evaluated with carotid ultrasound, pulse-wave velocity (PWV) and ankle-brachial index (ABI). Body composition was assessed wit DEXA method. Anatomical severity of CAD was evaluated with SYNTAX score. One-year composite endpoint included death, myocardial infarction, revascularization, stroke and hospitalization for cardiovascular reasons.

Results
The study group comprised 163 patients (mean age 59.8± years, 26% of females, n=43). Mean chemerin level was 284.8 ng/ml. There was no significant difference in chemerin concentrations between patients with diabetes and remaining ones (with prediabetes and with normal glucose levels) 306.8±121 vs 274.15±109 pg/ml, p=0.1. In Spearman test chemerin level correlated with total fat mass (R=0.15, p=0.047), trunk fat mass (R=0.16, p=0.039), android fat mass (R=0.16, p=0.036), and BMI (R=0.18, p=0.028). Chemerin also correlated with white blood cells (WBC) count (R=0.34, p&lt;0.0001), hsCRP (R=0.16, p=0.03), total cholesterol (R=0.17, p=0.028), LDL cholesterol (R=0.19, p=0.01), HDL cholesterol (R=−0.21, p=0.006), triglicerides (R=0.3, p&lt;0.0001), platelet count (R=0.23, p=0.002), fasting insulin (R=0.22, p=0.004) and c-peptide (R=0.26, p=0.0005). There was no significant difference in chemerin levels between patients with carotid atherosclerosis (n=93) and patients with normal carotid arteries (n=70), (300±124 vs 263±94 ng/ml, p=0.07). There were no significant associations between chemerin levels and PWV, ABI measurements, SYNTAX score, or 1-year prognosis.

Conclusions
This is the first study to show that in patients with CAD chemerin levels correlate with WBC and with android fat tissue mass. Additionally, chemerin levels positively correlated with other inflammation or insulin resistance markers, and with unfavourable lipid profile.

Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): The National Science Centre
A real-world comparison of outcomes between fractional flow reserve-guided versus angiography-guided percutaneous coronary intervention
Authors: Wong C , Ng A , Ada C , Chow V , Fearon W , Ng M , Kritharides L , Yong A 
Published: November 2020

Abstract

Background
Fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) has been shown to be superior to angiography-guided PCI in randomized controlled studies. However, real-world data on the use and outcomes of FFR-guided PCI remain limited.

Purpose
To investigate the outcomes of patients undergoing FFR-guided PCI compared to angiography-guided PCI in a large, state-wide unselected cohort.

Methods
All patients undergoing PCI between June 2017 and June 2018 recorded by the Centre for Health Record Linkage (CHeReL) were included in the study. The CHeReL database is one of the largest data linkage systems in Australia, capturing health data from ≥97% of all healthcare facilities in the state of New South Wales, which has a population of 7.5 million people. The PCI cohort was stratified into the FFR-guided group when a concomitant FFR procedure was performed, and the angiography-guided group when no FFR was performed. The primary endpoint was a combined endpoint of death or myocardial infarction (MI). Secondary endpoints included all-cause death, cardiovascular (CV) death, and MI.

Results
The cohort comprised 10,304 patients, of which 542 (5%) underwent FFR-guided PCI. There were no significant differences in age, gender, or comorbidities between the two groups. During a mean follow-up of 12±4 months, the FFR-guided PCI group had reduced occurrence of the primary endpoint (3% vs 8%, P&lt;0.001), all-cause death (1% vs 4%, P=0.001), CV death (1% vs 3%, P=0.01), and MI (2% vs 4%, P=0.01) (Figure). Multivariable Cox regression analysis demonstrated FFR-guidance to be an independent predictor of the primary endpoint (hazard ratio [HR] 0.47, 95% confidence interval [CI] 0.28–0.78, P=0.004), after adjusting for age, clinical presentation, comorbidities, and multi-vessel PCI. A sensitivity analysis was performed excluding patients that presented with acute MI, leading to a smaller cohort of 5,850 patients, of which 448 (8%) underwent FFR-guided PCI. FFR-guidance remained an independent predictor of the primary endpoint in this cohort of stable patients (HR 0.36, 95% CI 0.17–0.77, P=0.01).

Conclusion
In this real-world study of patients undergoing PCI, FFR-guidance was associated with improved clinical outcomes, driven by the lower hard endpoint of death or MI. The use of FFR-guided PCI remains limited worldwide, and efforts should be directed to increase adoption of this technique in future.
Figure 1

Funding Acknowledgement
Type of funding source: Foundation. Main funding source(s): National Heart Foundation of Australia Health Professional Scholarship
Comparison of clinical characteristics between patients with microvascular and epicardial coronary artery spasm
Authors: Kato K , Tateishi K , Saito Y , Kitahara H , Fujimoto Y , Kobayashi Y 
Published: November 2020

Abstract

Background
Coronary functional abnormalities including both epicardial and microvascular coronary artery spasm represent an important role responsible for myocardial ischemia in patients with angina and nonobstructive coronary artery disease. However, clinical characteristics associated with microvascular spasm (MVS) have not been fully evaluated.

Purpose
The aim of this study was to assess differences in clinical features between patients with MVS and epicardial coronary spasm.

Methods
A total of 732 consecutive patients with suspected angina who presented nonobstructive coronary arteries and underwent intracoronary acetylcholine provocation test were retrospectively enrolled in this study. Epicardial coronary spasm was defined as total or subtotal occlusion of epicardial coronary arteries accompanied by chest pain and/or ischemic electrocardiographic changes in response to acetylcholine provocation test. MVS was diagnosed when chest pain and/or ischemic electrocardiographic changes developed after administration of acetylcholine in the absence of epicardial coronary spasm. Clinical characteristics were compared between patients with MVS and epicardial coronary spasm.

Results
Of all patients, 83 patients (11%) had MVS, 367 (50%) had epicardial coronary spasm, and the other patients (39%) showed neither MVS nor epicardial coronary spasm. Patients with MVS tended to be older (65.6±12.7 vs. 63.0±12.3 years, P=0.088) and were more frequently female (60.2% vs. 41.1%, P=0.0016) in comparison with patients with epicardial coronary spasm. Patients with MVS were less likely to be smokers (8.6% vs. 22.9%, P=0.0018), while there were no significant differences in the other coronary risk factors such as hypertension, dyslipidemia, and diabetes mellitus. Serum uric acid were significantly lower in patients with MVS (4.9±1.1 vs. 5.4±1.3 mg/dl, P=0.0018).

Conclusion
Our study demonstrated that patients with MVS had distinctive clinical background from those with epicardial coronary spasm, suggesting different mechanisms may involve the development of MVS.

Funding Acknowledgement
Type of funding source: None
Unveiling coronary inflammation by perivascular fat angio-CT: a propensity-matched score analysis
Authors: Lopes Da Cunha G.J , Rocha B.M.L , Freitas P.N , Lopes P.M.D , Santos A.C , Guerreiro S , Abecasis J , Aguiar C.M.T , Andrade M.J , Saraiva C , Mendes M , Ferreira A 
Published: November 2020

Abstract

Background
Inflammation plays a pivotal role in the atherogenic process and recently has been the target of successful clinical trials. A new CT angiography method allows the identification of inflammatory pericoronary fat, which is associated with cardiovascular events. We aimed to determine whether patients with obstructive coronary artery disease (CAD) have a higher pericoronary inflammatory milieu when compared to those without CAD.

Methods
From a prospective CT angiography registry of patients with suspected obstructive CAD, those with a luminal stenosis &gt;70% confirmed by invasive coronary angiography were screened (previous coronary artery bypass grafting was an exclusion criteria). Subsequently, we applied a 1:1 propensity score (PS) without replacement protocol to match obstructive CAD patients with those without CAD (non-CAD), using age, gender, BMI, hypertension, dyslipidemia, diabetes and smoking status as covariates. Similar to previous reports, pericoronary fat characterization by CT angiography was performed by analyzing the fat attenuation index (FAI) at the −30 to −190 HU range. Inflammatory fat was defined by a FAI &gt;−70 HU. The proximal 50mm of the right coronary artery (RCA) was used to perform fat quantification and characterization. The perivascular fat was defined as the adipose tissue within a radial distance from the outer vessel wall equal to the diameter of the vessel.

Results
A matched cohort of 48 patients was identified (mean age 63 years; 77% males) – 24 obstructive CAD and 24 non-CAD patients. Mean FAI was numerically higher in obstructive CAD compared to the non-CAD cohort (−74±7 vs −78±7; p=0.083). Although not statistically significant, those with obstructive CAD had an increased proportion of inflammatory fat (51±10 vs 46±10%; p=0.107). After adjustment for body surface area (BSA), differences in the inflammatory fat proportion became apparent between obstructive CAD and non-CAD patients (28±6 vs 24±5%/m2; p=0.024). Furthermore, we observed a significant correlation between the inflammatory fat proportion (both absolute value and BSA adjusted) and the total number of RCA plaques (r=0.458; p=0.003; and r=0.451; p=0.003, respectively). Finally, there was 1 additional plaque observed in the RCA for each increase in 10% of proportion of inflammatory fat (p=0.018).

Conclusions
Perivascular coronary inflammation, as measured by FAI, seems significantly heightened in patients with obstructive CAD compared to a matched cohort of non-CAD patients. Further studies are needed to ascertain the mechanisms and possible implications of this association.

Funding Acknowledgement
Type of funding source: None
Risk stratification based on academic research consortium high bleeding risk criteria for long-term bleeding event after everolimus-eluting stent implantation
Authors: Miura K , Shimada T , Ohya M , Murai R , Amano H , Kubo S , Tada T , Tanaka H , Fuku Y , Goto T , Kadota K 
Published: November 2020

Abstract

Background
Recently, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria has been suggested as the standard definition of HBR.

Purpose
We aimed to investigate the risk stratification based on ARC-HBR Criteria for long-term bleeding event after everolimus-eluting stent implantation

Methods
The study population comprised 1193 patients treated with EES without in-hospital event between 2010 and 2011. Individual ARC-HBR criteria was retrospectively assessed. Major bleeding were defined as the occurrence of a Bleeding Academic Research Consortium type 3 or 5 bleeding event. The mean follow-up period was 2996±433 days.

Results
There were 656 patients (55.0%) in HBR-groups. Cumulative incidence of major bleeding was significantly higher in HBR-group (8.1% vs 3.4% at 4 year, and 16.2% vs 5.7% at 8 year, P&lt;0.001). Cumulative rate of major bleeding tend to be higher as the number of ARC-HBR criteria increased (≥2 Majors: 24.3%, 1 Major: 17.0%, ≥2 Minors:11.7%, and Non-HBR: 5.7%, P&lt;0.001).

Conclusion
ARC-HBR criteria successfully stratified the long-term bleeding risk after drug-eluting stent implantation in real-world practice.

Funding Acknowledgement
Type of funding source: None
European differences in characteristics, treatments and outcomes in patients with non-ST-elevation myocardial infarction – novel insights from four national real-world registries
Authors: Edfors R , Jernberg T , Lewinter C , Eha J , Asser P , Andreka P , Janosi A , Jortveit J , Halvorsen S 
Published: November 2020

Abstract

Background
Large-scale collection of standardized variables in patients with myocardial infarction (MI) in national real-world registries are only available in a few European countries and there is lack of cross-country comparisons.

Purpose
To compare demography, risk factors, hospital treatment and short- and long-term survival in patients hospitalized for non-ST elevation MI (NSTEMI) in four different European countries.

Methods
NSTEMI patients hospitalized and enrolled in national MI registries; EMIR (Estonia), HUMIR (Hungary), NORMI (Norway (2013–2016)) and SWEDEHEART (Sweden) from 2014 to 2017 were included.

Results
In total 119,191 patients with NSTEMI were included. The mean age at admission ranged from 70 years (Hungary) to 75 years (Estonia). The proportion of women was 36% in Sweden and 44% in Estonia. In Norway 24% were smokers, as compared to 17% in Sweden. Patients in Hungary had a high rate of diabetes mellitus (37%) and antihypertensive treatment (84%) but a low rate of lipid lowering treatment (32%). The proportion of patients with prior MI ranged from 28% (Norway) to 37% (Sweden). The presence of previous peripheral artery disease ranged from 7% (Sweden) to 17% (Hungary). The absolute proportion of performed coronary angiographies (58% versus 75%) and percutaneous coronary interventions (38% versus 56%), differed most between Norway and Hungary. Dual antiplatelet therapy ranged from 60% (Estonia) to 81% (Hungary) and statins from 78% (Norway) to 89% (Hungary), at discharge. The crude mortality rates at 1 month and 1 year are listed in table 1.

Conclusion
Cross-comparison of four national European MI registries provide new insights in differences in risk factors, treatment and outcomes. Possible reasons for the observed differences, include differences in the underlying expected mortality in the populations, inclusion-criteria and coverage of the registries and variable definitions, that need to be further explored.

Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Estonian Research Council